Seres Therapeutics (MCRB) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.01 million shs
Average Volume
6.44 million shs
Market Capitalization
$139.32 million
P/E Ratio
Dividend Yield
Price Target

Seres Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
443.5% Upside
$5.00 Price Target
Short Interest
14.17% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.24mentions of Seres Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$3,964 Sold Last Quarter
Proj. Earnings Growth
From ($1.02) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

251st out of 920 stocks

Pharmaceutical Preparations Industry

109th out of 429 stocks

MCRB stock logo

About Seres Therapeutics Stock (NASDAQ:MCRB)

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB Stock Price History

MCRB Stock News Headlines

Here's what to expect from Seres Therapeutics's earnings
Seres Therapeutics Inc
MCRB Apr 2024 1.000 put
Seres Therapeutics (MCRB) Gets a Buy from TD Cowen
Q4 2023 Seres Therapeutics Inc Earnings Call
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$126.85 million
Book Value
($0.39) per share


Free Float
Market Cap
$139.32 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 48)
    President, CEO & Director
    Comp: $1.02M
  • Dr. Lisa von Moltke M.D. (Age 65)
    Executive VP & Chief Medical Officer
    Comp: $725.15k
  • Dr. Teresa L. Young Ph.D. (Age 57)
    R.Ph., Executive VP and Chief Commercial & Strategy Officer
    Comp: $606.33k
  • Ms. Marella Thorell (Age 57)
    Executive VP & CFO
  • Dr. David S. Ege Ph.D. (Age 49)
    Executive VP & Chief Technology Officer
    Comp: $142.71k
  • Dr. Matthew R. Henn Ph.D. (Age 49)
    Executive VP & Chief Scientific Officer
    Comp: $643.83k
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 69)
    J.D., Chief Legal Officer, Executive VP & Secretary
    Comp: $719.55k
  • Ms. Caroline Holda
    Assistant General Counsel

MCRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price target for 2024?

2 brokers have issued 12 month price objectives for Seres Therapeutics' stock. Their MCRB share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 443.5% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2024?

Seres Therapeutics' stock was trading at $1.40 at the beginning of the year. Since then, MCRB stock has decreased by 34.3% and is now trading at $0.9199.
View the best growth stocks for 2024 here

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our MCRB earnings forecast

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its quarterly earnings data on Tuesday, March, 5th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.08. The biotechnology company earned $0.06 million during the quarter, compared to analysts' expectations of $0.50 million.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

Seres Therapeutics (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.46%), Price T Rowe Associates Inc. MD (0.20%), Mirae Asset Global Investments Co. Ltd. (0.03%) and BNP Paribas Financial Markets (0.03%). Insiders that own company stock include David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Moltke Lisa Von, Paula Cloghessy, Teresa L Young and Thomas Desrosier.
View institutional ownership trends

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MCRB) was last updated on 5/19/2024 by Staff

From Our Partners